Latest Ratios: P/E Ratio -100.3x · EV/EBITDA N/A · ROE N/A. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $340M | $329M | $23M | $150M | $133M | $646M | $638M | — |
| Enterprise Value | $410M | $399M | $97M | $237M | $227M | $532M | $644M | — |
| P/E Ratio → | -100.30 | — | — | — | — | — | — | — |
| P/S Ratio | 0.55 | 0.65 | 0.06 | 0.46 | 0.53 | 3.18 | 3.40 | — |
| P/B Ratio | — | — | 6.46 | 2.64 | 1.08 | 6.20 | 22.72 | — |
| P/FCF | 12.66 | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | 1256.83 | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.79 | 0.25 | 0.73 | 0.90 | 2.62 | 3.44 | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 15.2% | 15.2% | 13.7% | 18.4% | 20.6% | 20.1% | 19.7% | 19.3% |
| Operating Margin | -7.2% | -7.2% | -15.3% | -23.8% | -32.5% | -22.6% | -4.4% | -1.7% |
| Net Profit Margin | -12.1% | -12.1% | -16.4% | -25.6% | 0.1% | -5.4% | -7.6% | -2.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | — | — | -213.4% | -92.2% | 0.1% | -16.5% | -40.7% | -9.5% |
| ROA | -36.8% | -36.8% | -33.9% | -35.3% | 0.1% | -8.1% | -22.9% | -6.8% |
| ROIC | -49.7% | -49.7% | -40.9% | -32.0% | -59.3% | -285.7% | -16.7% | -5.0% |
| ROCE | -38.5% | -38.5% | -40.8% | -37.9% | -40.4% | -43.5% | -19.7% | -5.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 34.31 | 2.10 | 0.88 | 0.00 | 0.42 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | 20.47 | 1.51 | 0.76 | -1.10 | 0.21 | -0.06 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | -8.23 |
| Debt / FCF | — | — | — | — | — | — | — | -1.01 |
| Interest Coverage | -4.39 | -4.39 | -7.63 | -8.88 | -17.64 | -141.82 | -41.69 | -780.67 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.59 | 1.59 | 2.15 | 4.12 | 4.39 | 5.17 | 1.04 | 1.60 |
| Quick Ratio | 1.35 | 1.35 | 1.96 | 3.73 | 4.08 | 4.95 | 0.89 | 1.32 |
| Cash Ratio | 0.47 | 0.47 | 0.95 | 2.38 | 2.48 | 3.84 | 0.21 | 0.18 |
| Asset Turnover | — | 3.05 | 2.28 | 1.55 | 0.96 | 1.00 | 2.85 | 2.61 |
| Inventory Turnover | 25.26 | 25.26 | 33.81 | 19.35 | 21.64 | 25.19 | 34.60 | 32.26 |
| Days Sales Outstanding | — | 43.07 | 45.17 | 48.31 | 58.45 | 38.20 | 33.59 | 34.61 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | 7.9% | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.7% | 6.8% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.7% | 6.8% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $92M | $75M | $74M | $81M | $66M | $59M | $64M |
Includes 30+ ratios · 7 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying STLN stock.
Starling Oncology, Inc.'s current P/E ratio is -100.3x. This places it at the 50th percentile of its historical range.
Based on historical data, Starling Oncology, Inc. is trading at a P/E of -100.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Starling Oncology, Inc. has 15.2% gross margin and -7.2% operating margin.
Key Metrics
Top Statement Risk
Negative equity and thin margins
Metrics are mathematically derived from official filings.
Margins Recover but Remain Thin
According to quarterly financials, TOI's operating margin improved from -19.0% in 2024Q1 to -2.9% in 2026Q2, while gross margin hovered near 14-16%, indicating persistent cost pressure despite revenue growth.
The operating margin trend shows a clear inflection: losses narrowed from -$18.0M in 2024Q1 to -$4.6M in 2026Q2, a 74% reduction, per the income statement. However, gross margin remains thin and volatile, fluctuating between 12.6% and 16.5% over the period, suggesting limited pricing power in a competitive oncology services market. Net margin is still deeply negative at -6.1% in 2026Q2, implying that even with operating leverage, the company has not yet reached breakeven, and the path to profitability may be longer than the revenue acceleration suggests.
Capital Returns Deeply Negative
Based on reported figures, ROIC deteriorated from -10.0% in 2024Q1 to -41.0% in 2026Q2, while ROE turned sharply negative as equity eroded to -$24.9M, indicating severe value destruction on invested capital.
ROIC has worsened dramatically, from -10.0% in 2024Q1 to -41.0% in 2026Q2, even as revenue grows, because the capital base is shrinking while losses persist. ROE is not calculable in recent quarters due to negative equity, but when reported, it was -138.2% in 2024Q4, reflecting the impact of cumulative losses exceeding capital. The negative equity position suggests that the company is not compounding returns but rather consuming its capital base, and any recovery in ROIC will require both margin expansion and a stabilized equity base.
Working Capital Efficiency Improves
Per the latest quarterly data, TOI's cash conversion cycle shortened from 43 days in 2024Q1 to 18 days in 2026Q1, driven by faster receivables collection (DSO down from 49 to 36 days) and extended payables.
The cash conversion cycle has compressed significantly, from 43 days in 2024Q1 to 18 days in 2026Q1, as DSO fell from 49 to 36 days and DPO rose from 20 to 33 days, indicating improved working capital management. This efficiency gain contributed to the positive operating cash flow in 2026Q2, but the improvement may be partly due to revenue growth and timing, not structural change. Asset turnover also improved from 0.46 to 0.93 over the period, suggesting better revenue generation per dollar of assets, though this is partly a function of a shrinking asset base.
Debt Reduced but Equity Negative
As reported in balance sheet data, total debt fell from $119.8M in 2024Q1 to $24.6M in 2026Q2, but equity turned negative at -$24.9M, leaving the company with a strained capital structure despite lower leverage.
The debt reduction is substantial, with total debt down 79% over ten quarters, but the equity position has deteriorated to -$24.9M, indicating that the paydown was funded by asset liquidation and accumulated losses. Interest coverage remains negative, at -2.48 in 2026Q2, meaning operating income cannot cover interest expenses, though the absolute debt level is now lower. The negative equity suggests that the company is technically insolvent on a book basis, and any future financing may be constrained, though the shift to short-term debt (current ratio down to 1.36) warrants monitoring.
Liquidity Buffer Thins Rapidly
Based on quarterly ratios, TOI's current ratio fell from 3.08 in 2024Q1 to 1.36 in 2026Q2, while cash remained around $41M, indicating a shrinking liquidity cushion relative to short-term obligations.
The current ratio has more than halved over ten quarters, from 3.08 to 1.36, even though cash increased slightly to $41.1M, because current liabilities have grown faster, likely due to the shift to short-term debt. The quick ratio of 1.15 in 2026Q2 suggests that even without inventory, the company can cover near-term obligations, but the trend is concerning. Under a severe stress scenario, such as a revenue shortfall or margin compression, the liquidity position could become strained, especially given the negative equity and reliance on working capital swings for cash flow.
P/S Ratio Misleads on Value
The most commonly misapplied ratio for TOI is the price-to-sales multiple, which at 10.51 appears rich but obscures the fact that the company is unprofitable and has negative equity, making earnings-based or EV-based metrics more relevant.
With a P/S of 10.51, TOI trades at a premium to its revenue, but this multiple is misleading because the company has negative net income and negative equity, so the market is pricing in future profitability that has not yet materialized. EV/EBITDA is not meaningful because EBITDA is negative, and P/E is negative, so investors should focus on the trajectory of operating margins and cash flow generation rather than revenue multiples. A more appropriate metric would be EV/Revenue adjusted for the company's cash burn rate, or a forward-looking margin-based valuation, to assess whether the current market cap of roughly $1.7B (implied by P/S) is justified by the path to breakeven.